These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24456273)

  • 21. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
    Chapple CR
    BJU Int; 2004 Sep; 94(5):738-44. PubMed ID: 15329091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do we really need herbal medicine in LUTS/BPH treatment in the 21
    Pinggera GM; Frauscher F
    Expert Opin Drug Saf; 2016 Dec; 15(12):1573-1575. PubMed ID: 27461908
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH).
    Paterniti I; Campolo M; Cordaro M; Siracusa R; Filippone A; Esposito E; Cuzzocrea S
    Inflamm Res; 2018 Jul; 67(7):617-626. PubMed ID: 29679313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serenoa Repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia.
    Minutoli L; Bitto A; Squadrito F; Marini H; Irrera N; Morgia G; Passantino A; Altavilla D
    Curr Med Chem; 2013; 20(10):1306-12. PubMed ID: 23432584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What do I tell patients about saw palmetto for benign prostatic hyperplasia?
    Kane CJ; Raheem OA; Bent S; Avins AL
    Urol Clin North Am; 2011 Aug; 38(3):261-77. PubMed ID: 21798388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory effects of Ponciri Fructus on testosterone-induced benign prostatic hyperplasia in rats.
    Jeon WY; Kim OS; Seo CS; Jin SE; Kim JA; Shin HK; Kim YU; Lee MY
    BMC Complement Altern Med; 2017 Aug; 17(1):384. PubMed ID: 28774334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of Cucurbita pepo in the management of patients affected by lower urinary tract symptoms due to benign prostatic hyperplasia: A narrative review.
    Damiano R; Cai T; Fornara P; Franzese CA; Leonardi R; Mirone V
    Arch Ital Urol Androl; 2016 Jul; 88(2):136-43. PubMed ID: 27377091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia.
    Fitzpatrick JM; Lynch TH
    Urol Clin North Am; 1995 May; 22(2):407-12. PubMed ID: 7539185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH.
    Lowe FC; Dreikorn K; Borkowski A; Braeckman J; Denis L; Ferrari P; Gerber G; Levin R; Perrin P; Senge T
    Prostate; 1998 Nov; 37(3):187-93. PubMed ID: 9792136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Conservative treatment of benign prostatic hyperplasia].
    Romics I
    Orv Hetil; 2008 Oct; 149(40):1875-80. PubMed ID: 18815106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review.
    Wilt TJ; Ishani A; Stark G; MacDonald R; Lau J; Mulrow C
    JAMA; 1998 Nov; 280(18):1604-9. PubMed ID: 9820264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uvaria rufa Blume attenuates benign prostatic hyperplasia via inhibiting 5α-reductase and enhancing antioxidant status.
    Buncharoen W; Saenphet K; Saenphet S; Thitaram C
    J Ethnopharmacol; 2016 Dec; 194():483-494. PubMed ID: 27732901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phytotherapy for BPS. Which products can still be prescribed?].
    Madersbacher S; Schatzl G; Brössner C; Dreikorn K
    Urologe A; 2005 May; 44(5):513-20. PubMed ID: 15726313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of a phytotherapeutic agent, Eviprostat®, on prostatic and urinary cytokines/chemokines in a rat model of nonbacterial prostatitis.
    Sugimoto M; Oka M; Tsunemori H; Yamashita M; Kakehi Y
    Prostate; 2011 Mar; 71(4):438-44. PubMed ID: 21254154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.
    Buck AC
    J Urol; 2004 Nov; 172(5 Pt 1):1792-9. PubMed ID: 15540722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia.
    Sinescu I; Geavlete P; Multescu R; Gangu C; Miclea F; Coman I; Ioiart I; Ambert V; Constantin T; Petrut B; Feciche B
    Urol Int; 2011; 86(3):284-9. PubMed ID: 21304222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
    Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
    Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of D-004, a lipid extract from the Cuban royal palm fruit, on atypical prostate hyperplasia induced by phenylephrine in rats.
    Arruzazabala ML; Más R; Molina V; Noa M; Carbajal D; Mendoza N
    Drugs R D; 2006; 7(4):233-41. PubMed ID: 16784248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia.
    Hizli F; Uygur MC
    Int Urol Nephrol; 2007; 39(3):879-86. PubMed ID: 17203353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dietary supplements for benign prostatic hyperplasia: an overview of systematic reviews.
    Kim TH; Lim HJ; Kim MS; Lee MS
    Maturitas; 2012 Nov; 73(3):180-5. PubMed ID: 22883375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.